CHU de Bordeaux - service de rhumatologie
Bordeaux, France
NCT Number: NCT03575156
Our study aims at defining the role of circulating microparticles in the physiopathology of two rare auto-immune diseases: systemic lupus erythematosus (SLE) and systemic scleroderma (SSc). Microparticles might have an prognostic and diagnostic interest as well as potential for the discovery of new therapeutic strategies.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Bordeaux, France
Systemic lupus erythematosus (SLE) and systemic scleroderma (SSc) are two rare and potentially life-threatening auto-immune systemic diseases. There is an urgent need to describe prognostic factors and to discover new therapeutic pathways. Microparticles (MPs) are small extracellular vesicles formed from activated cells including endothelial cells and platelets. Preliminary data from our lab indicate that these MPs might play a key role in SLE and SSc physiopathology. In fact, MPs from patients with SLE aggregates with T regulator lymphocytes (LTregs) and decrease their activity, thereby promoting auto-immunity. Some works also indicate that MPs might cargo DNA to the immune system, also promoting auto-immunity. The investigators hypothesized that MPs levels might be a prognostic factor in SLE and SSc and that studying the molecular mechanisms involved could provide new therapeutic targets.
Our study will recruit 100 patients with SLE or SSc followed in Bordeaux University Hospital. Among classical disease activity information, blood and urine samples will be collected at each visit to study circulating microparticles. Fundamental research will be realized on patients' sample to study molecular mechanisms involved.
Clinical and biological disease activity, treatment and outcomes will be studied in correlation with MPs to describe their potential prognostic role. Patients will be followed at regular intervals as their usual follow-up would request. No extra visit will be needed and blood samples will be drawn at the same times as those drawn for clinical purposes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
6 ml
Time frame: At baseline (Day 0) and 12 months from baseline
Time frame: At baseline (Day 0) and 12 months from baseline
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)
Time frame: At baseline (Day 0) and 12 months from baseline
Rodnan score
Time frame: At baseline (Day 0) and 12 months from baseline
Time frame: At baseline (Day 0) and 12 months from baseline
University Hospital, Bordeaux
Other
Acronym: MICROLUPS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03816345
Arthritis, Arthritis, Psoriatic
Birmingham, Alabama, United States
View Trial DetailsNCT00522002
Arthritis, Arthritis, Rheumatoid
Washington D.C., District of Columbia, United States
View Trial DetailsNCT00010335
Arthritis, Arthritis, Juvenile
Seattle, Washington, United States
View Trial DetailsNCT07515638
Arthritis, Arthritis, Rheumatoid
Montpellier, France
View Trial Details